Recombinant Human ELFN2 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ELFN2 Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit neurite outgrowth of E16-E18 rat embryonic cortical neurons on a Laminin alpha 4 coated plate. Able to significantly inhibit neurite outgrowth when immobilized as a 3 μL droplet containing 300 ng of protein.
• Source: Human embryonic kidney cell, HEK293-derived human ELFN2 protein
  Asp23-Tyr397, with a C-terminal 6-His tag
• Accession #: Q5R3F8
• N-terminal Sequence: Asp23
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 43 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 71-94 kDa, non-reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ELFN2 Protein, CF

• dJ63G5.3 (putative Leucine rich protein)
• dJ63G5.3
• ELFN2
• extracellular leucine-rich repeat and fibronectin type III containing 2
• extracellular leucine-rich repeat and fibronectin type III domain containing 2
• extracellular leucine-rich repeat and fibronectin type III domain-containing protein 2
• KIAA1904
• leucine rich repeat containing 62
• leucine-rich repeat and fibronectin type-III domain-containing protein 6
• leucine-rich repeat-containing protein 62
• LRRC62
• PPP1R29
• protein phosphatase 1, regulatory subunit 29

Background

ELFN2 (Extracellular leucine-rich repeat and fibronectin type III domain-containing protein 2), also known as protein phosphatase 1 regulatory subunit 29, is a member of the extracellular Leucine-Rich Repeat superfamily (1). Expressed mainly in the nervous system, ELFN2 is a transmembrane protein that inhibits the activity of protein phosphatase 1 (PP1) complexes (2). Mature human ELFN2 consists of a 375 aa extracellular domain (ECD), a 21 aa transmembrane segment and a 402 aa cytoplasmic tail. The ECD includes one fibronectin type-III domain, five leucine-rich repeats (LRR) and one LRR C-terminal (LRRCT) domain. Human ELFN2 shares 98% aa sequence identity with mouse and rat ELFN2. Expression of ELFN2 is quite restricted to the nervous system in which it is broadly expressed in the cortex in presumed glutamatergic neurons, in hippocampal pyramidal and granule cells, and in the striatum. These patterns are maintained in adults. Given the functions and discrete patterns of many known LRR family proteins it has been proposed that ELFN2 could provide the requisite specificity of cellular interactions to mediate a large number of selective connectivity decisions involved in neurite outgrowth, axon guidance, fasciculation, and synapse formation (1). Mutations of ELFN2 have been reported in pancreatic cancer radiation resistance (3) and stress fracture (4).

1. Dolan J. et al. (2007) BMC Genomics 8:320.
2. Hendrickx, A. et al. (2009) Chem. Biol. 16:365.
3. Friedman E. et al. (2014) Genet Res (Camb) 96:e004.
4. Souchek L.L. et al. (2014) British Journal of Cancer 111:1139.

Bioinformatics

• Uniprot:
  • Q5R3F8()